Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 47 Parkinson's papers of 851 | 0.49 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2399
Sealed predictions
- CTSD in dopamine neurons, braak+0.08 (p 0.833) → +0.81 (p 0.008)receipt 2407
In the sealed studies
- An antigen-presenting microglial response: did not hold
Swarm cases
receipt 2407: CTSD in dopamine neurons, braak
- power
- full sample +0.54 (p 0.021, n 18), 95% CI +0.10 to +0.80. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.62 (p 0.0057, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.56 (p 0.016, n 18). not the mix.
- skeptic
- leave-one-out range +0.48 to +0.65, sign flips 0; without severely affected donors +0.54 (p 0.021, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CTSD in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts